Skip to main content
. 2022 Sep 26;10:1003976. doi: 10.3389/fpubh.2022.1003976

Figure 4.

Figure 4

PSM-adjusted OS and BCSS of patients with BMBC in the neoadjuvant chemotherapy plus surgical treatment and chemotherapy alone groups (stratified by metastatic modality). Kaplan–Meier (K–M) survival analysis: (A) OS of patients with bone metastases only; (B) OS of patients with bone and liver metastases; (C) OS of patients with bone and lung metastases; (D) OS of patients with bone and liver and lung metastases; (E) OS of patients with BMBC combined with brain metastases; (F) BCSS of patients with bone metastases only; (G) BCSS of patients with bone and liver metastases; (H) BCSS of patients with bone and lung metastases; (I) BCSS of patients with bone and liver and lung metastases; (J) BCSS of patients with BMBC combined with brain metastases. OS, overall survival; BCSS, breast cancer-specific survival; PSM, Propensity score matching; BMBC, bone metastatic breast cancer.